Carcinogen‐induced tumors in SFN‐transgenic mice harbor a characteristic mutation spectrum of human lung adenocarcinoma by キム ユンジュン et al.
Carcinogen‐induced tumors in SFN‐transgenic
mice harbor a characteristic mutation spectrum
of human lung adenocarcinoma
著者（英） Yunjung Kim, Aya Shiba‐Ishii, Karina Ramirez,









権利 This is an open access article under the terms
of the Creat ive Commo ns Attri bution-NonCo
mmercial License, which permits use,
distribution and reproduction in any medium,
provided the original work is properly cited
and is not used for commercial purposes. (C)
2019 The Authors. Cancer Science published by




Creative Commons : 表示 - 非営利
http://creativecommons.org/licenses/by-nc/3.0/deed.ja
Cancer Science. 2019;110:2431–2441.	 	 	 | 	2431wileyonlinelibrary.com/journal/cas
 
Received:	18	April	2019  |  Revised:	16	May	2019  |  Accepted:	28	May	2019
DOI: 10.1111/cas.14081  
O R I G I N A L  A R T I C L E
Carcinogen‐induced tumors in SFN‐transgenic mice 
harbor a characteristic mutation spectrum of human lung 
adenocarcinoma
Yunjung Kim1 |   Aya Shiba‐Ishii1  |   Karina Ramirez2 |   Masafumi Muratani3 |   



























only	 in	 the	 lung.	Here,	we	have	 found	 that	carcinogen	nicotine-derived	nitrosami-









adenocarcinoma	 patients.	 Additionally,	 mutated	 genes	 in	 Tg-SPC-SFN+/−	 tumors	
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cancer	 and	 non-small-cell	 lung	 cancer	 (NSCLC).3	 Lung	 adenocar-
cinoma,	 the	 predominant	 type	 of	NSCLC,	 is	 considered	 to	 show	
a	multistep	process	of	carcinogenesis.	Atypical	adenomatous	hy-
perplasia	progresses	to	adenocarcinoma	in	situ,	and	subsequently	
to	 invasive	 adenocarcinoma	 with	 specific	 molecular	 alterations	
that	 are	 responsible	 for	 both	 the	 initiation	 and	 maintenance	 of	
tumorigenesis.4
Previously,	we	 examined	 the	 gene	 expression	 profiles	 of	 early	




SFN	 is	due	 to	DNA	hypomethylation	 in	 its	promoter	 region7,8 and 
is	 associated	with	poor	patient	outcome	 in	 lung	adenocarcinoma.9 














many	 studies	 have	 revealed	 comprehensive	 somatic	 mutations	 in	
advanced	 lung	 adenocarcinomas	 using	 whole-exome	 sequencing	
(WES),13	which	has	high	accuracy,	 high	 sensitivity,	 and	 cost	 effec-
tiveness	for	identifying	driver	mutations14,15	and	can	predict	the	ef-




els	 of	 oncogenetic	 activation	 show	 frequent	 aneuploidy	 and	 copy	
number	 alteration,	 but	 few	 somatic	 single-nucleotide	 variants.17 
However,	carcinogens	such	as	methyl-nitrosourea	and	nicotine-de-









In	 the	 present	 study,	 we	 investigated	 the	 genetic	 landscape	
of	NNK-induced	 lung	adenocarcinomas	 in	a	Tg-SPC-SFN+/−	back-
ground.	 Paired	 samples	 of	 tumor	 tissue	 and	 normal	 lung	 were	
subjected	to	WES,	and	mutated	genes	associated	with	SFN	over-
expression	 in	 lung	 adenocarcinoma	 were	 examined.	 Here,	 we	
emphasize	the	importance	of	SFN	overexpression	in	lung	adeno-
carcinogenesis	and	show	that	Tg-SPC-SFN+/− mice provide a valu-
able	model	 for	 clarifying	early	genetic	alterations	 in	human	 lung	
adenocarcinoma.
2  | MATERIAL S AND METHODS




scribed previously.11	Wild-type	(WT)	and	Tg-SPC-SFN+/− mice were 
given	a	single	i.p.	dose	of	4	mg	NNK	(Toronto	Research	Chemicals,	
North	York,	ON,	Canada)	 dissolved	 in	 saline	 to	 induce	 pulmonary	
tumors.	Twenty	weeks	 after	NNK	 treatment,	 all	 of	 the	mice	were	
killed,	 and	 the	 induced	 tumors	were	 resected	 from	 the	 lungs.	The	
resected	 tumors	were	partially	 fixed	with	 formalin	 for	histological	
analysis	 including	 hematoxylin	 and	 eosin	 (H&E)	 staining	 and	 im-
munohistochemistry	 for	 hSFN,	 as	 described	previously,11 and also 
frozen	in	liquid	nitrogen	for	WES	and	stored	at	−80°C	until	DNA	ex-
traction.	All	animal	experiments	were	approved	by	the	Institutional	
Animal	 Experiment	 Committee	 of	 the	 University	 of	 Tsukuba	
(Tsukuba,	Japan).










mapped	 to	 the	 GRCm38/mm10	 mouse	 reference	 and	 annotated	
using	Ensemble,	Hanava,	or	Ensemble	and	Hanava	merged	transcript	
database.	(http://www.ensem	bl.org/index.html)	
Possible	 single-nucleotide	polymorphisms	or	 possible	 ICR	drift	
mutations	were	 excluded	 from	 the	data	 as	 follows:	 (a)	 single	base	













T:A>C:G,	 or	 T:A>G:C).	 Here,	 we	 used	 pyrimidines	 to	 denote	 each	
group	such	as	C>A,	C>G,	C>T,	T>A,	T>C,	and	T>G,	and	counted	the	
number	 of	mutations	 detected	 in	 tumor	 samples	 from	WT	 or	 Tg-












Ingenuity	 Pathway	 Analysis	 (IPA;	 Qiagen)	 or	 Kyoto	 Encyclopedia	
of	 Genes	 and	Genomes	 (KEGG)	 pathway	 analysis	 through	DAVID	
Bioinformatics	Resources	6.8.	(https	://david.ncifc	rf.gov/)	
2.4 | Expression analysis of mutated genes in human 
lung adenocarcinoma
Mutation	 profiles,	 gene	 expression	 profiles,	 and	 clinical	 data	 for	
482	cases	of	lung	adenocarcinoma	from	The	Cancer	Genome	Atlas	
(TCGA)	 database	 (https	://portal.gdc.cancer.gov/)	were	 used	 to	 ex-
plore	mutation	frequency	and	 its	correlation	with	patient	survival.	
The	percentage	of	lung	adenocarcinoma	patients	having	a	mutation	


































For	 the	 significant	 canonical	 pathways	 associated	 with	 mutated	





3.1 | Histological examination of tumors attributed 










trol	 into	Tg-SPC-SFN+/−	 and	WT	mice	 (Figure	1A).	 Twenty	weeks	
after	the	treatment,	we	killed	all	mice	and	collected	the	lungs	and	
developing	 tumors,	which	were	 divided	 into	 2	 parts:	 histological	
examinations	and	WES.	First,	we	undertook	H&E	staining	to	exam-
ine	 the	histology	of	 tumors	 that	developed	 in	Tg-SPC-SFN+/− and 
WT	mice.	 Although	 10	 tumors	 developed	 in	 Tg-SPC-SFN+/− mice 
and	 we	 selected	 4	 tumors	 that	 were	 sufficient	 size	 to	 examine	
WES,	 most	 WT	 tumors	 were	 small	 and	 detected	 in	 the	 central	
area	of	the	lung	when	we	undertook	histological	examinations.	We	
obtained	fresh	material	from	only	one	WT	tumor	to	be	applied	to	
WES.	 Interestingly,	tumors	that	developed	in	Tg-SPC-SFN+/− mice 
showed	 papillary	 or	 lepidic	 differentiation,	 which	 are	 major	 his-
tologic	 subtypes	 of	 human	 lung	 adenocarcinoma,	whereas	 those	
in	WT	mice	 showed	 the	 tendency	 to	 have	 poorer	 differentiated	
histology	 (Figure	 1B,C).	Moreover,	 by	 immunohistochemistry,	we	
confirmed	that	tumors	developing	 in	Tg-SPC-SFN+/− mice showed 
positivity	 for	 hSFN	 (Figure	 1C).	 These	 results	 indicated	 that	 the	
transgenic	mice	had	been	generated	successfully	with	appropriate	
gene	recombination.	As	overexpression	of	SFN	is	a	common	event	
facilitating	 tumor	 progression	 in	most	 human	 invasive	 adenocar-
cinomas,5,9	we	 speculated	 that	 genetic	 alterations	 in	 tumors	 that	
developed	in	Tg-SPC-SFN+/−	mice	might	mimic	those	in	human	lung	
adenocarcinoma.
3.2 | Whole‐exome sequencing reveals exonic 
mutational signatures in Tg‐SPC‐SFN+/− tumors
We	 undertook	 WES	 using	 paired	 samples	 of	 normal	 lung	 and	
tumor	 tissue	described	 in	Table	1	 to	 identify	genetic	alterations	
due	to	overexpression	of	hSFN	(Tables	S1	and	S2).	After	exclud-
ing	 single-nucleotide	 polymorphisms,	 the	 mean	 number	 of	 so-
matic	mutations	in	4	samples	of	Tg-SPC-SFN+/−	tumors	was	373.8	
(Figure	S1B).	Among	nonsynonymous	somatic	mutations,	7.3%	of	
them	 in	 average	were	nonsense	mutations	 in	Tg-SPC-SFN+/−	 tu-
mors,	 which	 included	 several	 tumor	 suppressor	 genes,	 such	 as	
Banp, Smarcc1, Epha3, Ccdc154,	and	Ing5	(Figure	S1C).	Therefore,	
we	expect	that	these	tumor	suppressor	genes	harboring	nonsense	
mutations	might	 produce	 incomplete	 forms	 and	 possibly	 induce	
tumor	progression.
Moreover,	 according	 to	 previous	 reports,	 frequent	 somatic	
mutation	 of	 T>C	 or	 T>G	 in	 mice	 is	 caused	 by	 spontaneous	 point	
Sex Treatment Strain Tissue type Genotype
WT-CON Male Saline ICR Normal Wild	type
Tg-CON Male Saline ICR Normal Tg-SPC-SFN+/−
WT Male NNK ICR Normal Tg-SPC-SFN+/−
Adenoma
Tg1 Male NNK ICR Normal Tg-SPC-SFN+/−
Adenoma
Tg2 Male NNK ICR Normal Tg-SPC-SFN+/−
Adenoma
Tg3 Male NNK ICR Normal Tg-SPC-SFN+/−
Adenoma




TA B L E  1  Details	of	samples	used	for	
whole-exome	sequencing	analysis
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mutations,	unlike	the	situation	in	humans.22	Consistently,	as	shown	
in	Figure	2A,	WT	tumor	showed	a	high	frequency	of	T>C	and	T>G.	




We	also	examined	 the	mutational	 signatures	of	Tg-SPC-SFN+/− 
and	WT	tumor.	On	the	basis	of	the	COSMIC	database,	the	signatures	
of	Tg-SPC-SFN+/−	tumors	were	similar	to	the	COSMIC	signatures	4	















high	 mutation	 number	 showed	 significantly	 higher	 expression	 of	











ical	 indicator	of	 the	efficacy	of	 immune	 checkpoint	 inhibitors.16,25 




























to	 transversion	 (Ts/Tv)	 ratio	 is	known	to	be	widely	variable	across	
tumor	 types	 depending	 on	 the	 mutagens	 involved	 or	 the	 mech-









3.4 | Frequently mutated genes in Tg‐SPC‐
SFN+/− tumors







that	 Blm, Brd4, Dnmt3b, Herc2, Nlrp2,	 and	 Smg1 were common 
mutated	 genes	 in	 3	 samples	 of	 Tg-SPC-SFN+/−	 tumors,	 whereas	
67	other	genes,	 including	Cdc20, Cdh23, Cul9, Fgf7, Itga6, Kmt2c, 
Mki67, Tbc1d9,	and	Tsc2,	were	present	in	two	samples	of	Tg-SPC-
SFN+/−	 tumors	 (Figure	 4B).	Notably,	 8	 genes	 contained	 identical	
mutation	sites	among	Tg-SPC-SFN+/−	 tumors,	 including	G235E	 in	
Blm,	 I108V	 and	 R124C	 in	 Smg1,	 I92V	 in	Ctbs,	 S283G	 in	Cyb5r2,	
S153A	 in	 Fgf7,	 D665E/H	 in	 Kmt2c,	 H366R	 in	Ovch2,	 and	 L575I	







Moreover,	 Tg-SPC-SFN+/−	 tumors	 showed	 accumulation	 of	
passenger	 gene	 and	 tumor	 suppressor	 gene	 mutations	 such	 as	
Blm, Dnmt3b, Cyb5r2, Dapk1, Foxp3, Kmt2c,	and	Tsc2	 rather	 than	
a	specific	driver	oncogene	mutation,	such	as	Kras	mutation	in	WT	
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lated	to	PI3K/AKT	signaling,	such	as	Fgf7, Itga6, Synj2,	and	Tsc2 and 
the	apoptosis	signaling	pathway	(Figure	5A	and	Table	S5).
We	then	collected	all	mutated	genes	in	4	Tg-SPC-SFN+/−	tumors	
and	 investigated	 pathways	 that	 were	 significantly	 enriched	 using	
the	KEGG	pathway	and	IPA	software.	The	KEGG	pathway	analysis	
revealed	 that	 mutated	 genes	 in	 Tg-SPC-SFN+/−	 tumors	 were	 sig-
nificantly	associated	with	pathways	 in	cancer,	ubiquitinated	prote-
olysis,	small-cell	 lung	cancer,	 the	PI3K-AKT	signaling	pathway,	and	
transcriptional	misregulation	 in	 cancer	 (Table	 S6).	 In	 contrast,	 IPA	
software	 analysis	 indicated	 that	 Tg-SPC-SFN+/−	 tumors	 harbored	
gene	 mutations	 that	 were	 significantly	 correlated	 with	 canonical	
pathways	 such	 as	 14-3-3-mediated	 signaling,	 apoptosis	 signaling,	
PTEN	 signaling,	 and	 DNA	 double-strand	 break	 repair	 by	 homolo-
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MKI67, ITGA6,	 or	CDC20	 had	 a	 significantly	 poorer	 outcome	 than	
those	with	low	expression	of	the	genes	(Figure	S4A).	In	contrast,	pa-
tients	with	high	expression	of	NLRP2, CUL9, TBC1D9,	or	CDH23 had 
a	 significantly	more	 favorable	 outcome	 relative	 to	 those	with	 low	
expression	of	these	genes	(Figure	S4B).
In	 summary,	 overexpression	 of	 SFN	 might	 frequently	 induce	 a	
large	number	of	mutations,	most	of	which	are	involved	in	PI3K/AKT	


















induced	 tumors	 in	Tg-SPC-SFN+/−	mice,11	we	consider	 that	overex-
pression	of	hSFN	in	the	lung	in	ICR	mice	robustly	induces	initiation	
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of	 tumor	 formation,	 similar	 to	NNK	exposure.	Moreover,	 all	NNK-
induced	tumors	in	Tg-SPC-SFN+/−	mice	have	high	similarity	to	most	
human	 lung	 adenocarcinomas	 in	 terms	 of	 histology33	 and	 genetic	
profiles,	 including	a	high	frequency	of	passenger	mutations,	a	high	
frequency	of	transversion,	a	large	mutation	burden,	and	smoking-like	























indicate	 the	cause	of	 somatic	mutations	 such	as	DNA	replication	
infidelity,	 defective	 DNA	 repair	 processes,	 and	 mutagen	 expo-
sure	occurring	throughout	life.40	Among	30	mutational	signatures	
in	 the	COSMIC	 database,	 signature	 4	 is	 the	most	 closely	 related	
to	 lung	 cancers	 associated	 with	 smoking,23,39	 and	 signature	 24	
is	 linked	 to	 liver	 cancer	 and	 exposure	 to	 aflatoxin,	 a	 carcinogen	
produced	 by	 fungi	 in	 nature,39	 both	 of	 which	 show	 similarity	 to	
Tg-SPC-SFN+/−	tumors.
Through	 interaction	 with	 the	 target	 proteins,	 14-3-3	 proteins	




assume	 that	 the	high	number	of	gene	mutations	 in	Tg-SPC-SFN+/− 
tumors	might	 be	 due	 to	 binding	with	 unknown	 factor(s),	 which	 is	
associated	with	the	DNA	repair	system.	SFN	might	inhibit	DNA	re-
pair-related	factors,	resulting	in	the	accumulation	of	numerous	gene	
mutations.	 Indeed,	we	 found	 some	mutated	genes	 involved	 in	 the	
DNA	damage	response	and	repair	system	such	as	Blm, Brd4, Herc2, 
Brca1, Pole, Ddb1, Msh6,	 and	 Xrcc1	 only	 in	 Tg-SPC-SFN+/−	 tumors	
(Table	 S5),	 suggesting	 that	 these	 alterations	 could	 also	 indirectly	





















tations	of	Blm, Dnmt3b, Mki67, Itga6, Cdc20, Nlrp2, Cul9, Tbc1d9,	and	






by	 SFN,	 further	 verification	 and	 functional	 analysis	 using	 human	
lung	adenocarcinoma	specimens	will	be	needed	 in	order	to	under-


















SFN	overexpression	 is	 critical	 to	human	 lung	adenocarcinogenesis	
and	that	our	mouse	model,	created	by	both	genetic	engineering	and	
carcinogen	 exposure,	would	 be	 a	 valuable	 resource	 for	 preclinical	
examinations	of	therapy	for	lung	adenocarcinoma.
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